WO2002028346A3 - Association d'un antagoniste du recepteur cb1 et de sibutramine, pour le traitement de l'obesite - Google Patents

Association d'un antagoniste du recepteur cb1 et de sibutramine, pour le traitement de l'obesite Download PDF

Info

Publication number
WO2002028346A3
WO2002028346A3 PCT/FR2001/003022 FR0103022W WO0228346A3 WO 2002028346 A3 WO2002028346 A3 WO 2002028346A3 FR 0103022 W FR0103022 W FR 0103022W WO 0228346 A3 WO0228346 A3 WO 0228346A3
Authority
WO
WIPO (PCT)
Prior art keywords
sibutramin
association
receptor antagonist
treating obesity
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2001/003022
Other languages
English (en)
Other versions
WO2002028346A2 (fr
Inventor
Odile Piot-Grosjean
Philippe Picaut
Francois Petitet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8854974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002028346(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EA200300441A priority Critical patent/EA005924B1/ru
Priority to BR0114410-3A priority patent/BR0114410A/pt
Priority to AU9393601A priority patent/AU9393601A/xx
Priority to DK01974413T priority patent/DK1328269T5/da
Priority to NZ524904A priority patent/NZ524904A/en
Priority to SK403-2003A priority patent/SK4032003A3/sk
Priority to MXPA03002845A priority patent/MXPA03002845A/es
Priority to IL15523601A priority patent/IL155236A0/xx
Priority to HU0302044A priority patent/HUP0302044A3/hu
Priority to JP2002531972A priority patent/JP4221221B2/ja
Priority to SI200130139T priority patent/SI1328269T2/sl
Priority to CA002424934A priority patent/CA2424934A1/fr
Priority to AU2001293936A priority patent/AU2001293936B2/en
Priority to HR20030249A priority patent/HRP20030249A2/hr
Priority to EEP200300121A priority patent/EE200300121A/xx
Priority to PL01362833A priority patent/PL362833A1/xx
Priority to KR10-2003-7004772A priority patent/KR20030036885A/ko
Priority to EP01974413A priority patent/EP1328269B2/fr
Priority to AT01974413T priority patent/ATE267595T1/de
Priority to DE60103556T priority patent/DE60103556T3/de
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of WO2002028346A2 publication Critical patent/WO2002028346A2/fr
Publication of WO2002028346A3 publication Critical patent/WO2002028346A3/fr
Priority to NO20031521A priority patent/NO20031521L/no
Anticipated expiration legal-status Critical
Priority to BG107739A priority patent/BG107739A/bg
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne l'association d'un antagoniste du récepteur CB1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de l'obésité.
PCT/FR2001/003022 2000-10-04 2001-10-01 Association d'un antagoniste du recepteur cb1 et de sibutramine, pour le traitement de l'obesite Ceased WO2002028346A2 (fr)

Priority Applications (22)

Application Number Priority Date Filing Date Title
BR0114410-3A BR0114410A (pt) 2000-10-04 2001-10-01 Associação de um antagonista de receptor cb1 e de sibutramina, as composições farmacêuticas que os contêm e a respectiva utilização para o tratamento da obesidade
AU2001293936A AU2001293936B2 (en) 2000-10-04 2001-10-01 Association of the CB1 receptor antagonist and sibutramin, for treating obesity
AU9393601A AU9393601A (en) 2000-10-04 2001-10-01 Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
DK01974413T DK1328269T5 (da) 2000-10-04 2001-10-01 Kombination af en CB1-receptorantagonist og sibutramin til behandling af fedme
NZ524904A NZ524904A (en) 2000-10-04 2001-10-01 Association of the CB1 receptor antagonist and a sibutramine for treating obesity
SK403-2003A SK4032003A3 (en) 2000-10-04 2001-10-01 Association of the CB1 receptor antagonist and sibutramin, for treating obesity
MXPA03002845A MXPA03002845A (es) 2000-10-04 2001-10-01 Asociacion de un antagonista del receptor cb1 y de sibutramina, las composiciones farmaceuticas que los contienen y su utilizacion para el tratamiento de la obesidad.
IL15523601A IL155236A0 (en) 2000-10-04 2001-10-01 Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
HU0302044A HUP0302044A3 (en) 2000-10-04 2001-10-01 Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
JP2002531972A JP4221221B2 (ja) 2000-10-04 2001-10-01 Ｃｂ１受容体アンタゴニストおよびシブトラミンの組み合わせ、それらからなる医薬組成物、および肥満の治療におけるそれらの使用
SI200130139T SI1328269T2 (sl) 2000-10-04 2001-10-01 Kombinacija antagonista CB1 receptorja in sibutramina za zdravljenje obezitete
EEP200300121A EE200300121A (et) 2000-10-04 2001-10-01 CB1 retseptori antagonisti ja sibutramiini kombinatsioon, neid sisaldav farmatseutiline kompositsioon ja kasutamine lihavuse raviks
HR20030249A HRP20030249A2 (en) 2000-10-04 2001-10-01 Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
EA200300441A EA005924B1 (ru) 2000-10-04 2001-10-01 Ассоциация или комбинация антагониста рецептора cb1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
CA002424934A CA2424934A1 (fr) 2000-10-04 2001-10-01 Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de l'obesite
PL01362833A PL362833A1 (en) 2000-10-04 2001-10-01 Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
KR10-2003-7004772A KR20030036885A (ko) 2000-10-04 2001-10-01 Ｃｂ1 수용체 길항제와 시부트라민과의 조합물, 이를함유하는 약제학적 조성물 및 비만을 치료하기 위한 이의용도
EP01974413A EP1328269B2 (fr) 2000-10-04 2001-10-01 Association d'un antagoniste du recepteur cb1 et de la sibutramine pour le traitement de l'obesite
AT01974413T ATE267595T1 (de) 2000-10-04 2001-10-01 Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1- rezeptoren und sibutramine enthalten
DE60103556T DE60103556T3 (de) 2000-10-04 2001-10-01 Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1-rezeptoren und sibutramine enthalten
NO20031521A NO20031521L (no) 2000-10-04 2003-04-03 Assosiasjon av CB1-reseptorantagonist og et sibutramin, farmasöytiske preparater inneholdende denne samt dens anvendelse for behandling avfedme
BG107739A BG107739A (bg) 2000-10-04 2003-04-17 Комбинация от антагонист на св1 рецептор и сибутрамин, фармацевтични състави, които ги съдържат, и използването им за лечение на затлъстяване

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR00/12646 2000-10-04
FR0012646A FR2814678B1 (fr) 2000-10-04 2000-10-04 Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite

Publications (2)

Publication Number Publication Date
WO2002028346A2 WO2002028346A2 (fr) 2002-04-11
WO2002028346A3 true WO2002028346A3 (fr) 2002-08-29

Family

ID=8854974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/003022 Ceased WO2002028346A2 (fr) 2000-10-04 2001-10-01 Association d'un antagoniste du recepteur cb1 et de sibutramine, pour le traitement de l'obesite

Country Status (29)

Country Link
EP (1) EP1328269B2 (fr)
JP (1) JP4221221B2 (fr)
KR (1) KR20030036885A (fr)
CN (1) CN100409845C (fr)
AT (1) ATE267595T1 (fr)
AU (2) AU2001293936B2 (fr)
BG (1) BG107739A (fr)
BR (1) BR0114410A (fr)
CA (1) CA2424934A1 (fr)
DE (1) DE60103556T3 (fr)
DK (1) DK1328269T5 (fr)
EA (1) EA005924B1 (fr)
EE (1) EE200300121A (fr)
ES (1) ES2217191T5 (fr)
FR (1) FR2814678B1 (fr)
HR (1) HRP20030249A2 (fr)
HU (1) HUP0302044A3 (fr)
IL (1) IL155236A0 (fr)
MX (1) MXPA03002845A (fr)
NO (1) NO20031521L (fr)
NZ (1) NZ524904A (fr)
PL (1) PL362833A1 (fr)
PT (1) PT1328269E (fr)
SI (1) SI1328269T2 (fr)
SK (1) SK4032003A3 (fr)
TR (1) TR200401264T4 (fr)
WO (1) WO2002028346A2 (fr)
YU (1) YU26103A (fr)
ZA (1) ZA200303015B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833842B1 (fr) * 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
WO2003075917A1 (fr) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Polytherapie destinee a traiter, prevenir ou gerer des troubles proliferatifs et des cancers
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
AU2003215024B2 (en) 2002-03-26 2008-02-21 Merck Sharp & Dohme Corp. Spirocyclic amides as cannabinoid receptor modulators
EP1492784A4 (fr) 2002-03-28 2006-03-29 Merck & Co Inc 2,3-diphenyl-pyridines substituees
AU2003223510B2 (en) 2002-04-12 2008-05-08 Merck Sharp & Dohme Corp. Bicyclic amides
JP4202319B2 (ja) 2002-07-29 2008-12-24 エフ．ホフマン−ラ ロシュ アーゲー 新規ベンゾジオキソール
KR100674769B1 (ko) 2003-01-02 2007-02-28 에프. 호프만-라 로슈 아게 신규 씨비 1 수용체 역작용제
CN101012193A (zh) 2003-01-02 2007-08-08 霍夫曼-拉罗奇有限公司 新cb 1受体反激动剂
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
CN1802351A (zh) 2003-06-11 2006-07-12 麦克公司 被取代的3－烷基和3－链烯基氮杂环丁烷衍生物
RU2344132C2 (ru) 2003-06-20 2009-01-20 Ф.Хоффманн-Ля Рош Аг 2-аминобензотиазолы в качестве обратных агонистов рецепторов cb1
EP1498123A1 (fr) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Systèmes émulsifiants contenant des dérivés d'azétidine
EP1498122A1 (fr) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Systèmes semi-solides contenant des dérivés d'azétidine
EP1663215A1 (fr) * 2003-09-02 2006-06-07 Solvay Pharmaceuticals GmbH Nouvelle utilisation medicale d'antagonistes selectifs du receptor cb1
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
WO2005049615A1 (fr) * 2003-11-21 2005-06-02 Pfizer Products Inc. Derives de pyrazolo[1,5-a][1,3,5]triazin-4-one en tant qu'antagonistes des recepteurs cb1
WO2005058887A1 (fr) 2003-12-08 2005-06-30 F. Hoffmann-La Roche Ag Nouveaux derives de thiazole
ES2349195T3 (es) 2004-01-28 2010-12-28 F. Hoffmann-La Roche Ag Espiro-benzodioxoles y su uso como antagonistas de cb1.
ES2324720T3 (es) 2004-05-10 2009-08-13 F. Hoffmann-La Roche Ag Pirrol o imidazol amidas para tratar la obesidad.
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
EP1807070A1 (fr) * 2004-09-29 2007-07-18 Schering Corporation Combinaisons d'azetidinones substituees et d'antagonistes cb1
FR2876689B1 (fr) * 2004-10-14 2008-02-22 Aventis Pharma Sa Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
JP2008517976A (ja) 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
AU2005298986A1 (en) 2004-10-27 2006-05-04 F. Hoffmann-La Roche Ag New indole or benzimidazole derivatives
JP4675969B2 (ja) 2004-11-09 2011-04-27 エフ．ホフマン−ラ ロシュ アーゲー ジベンゾスベロン誘導体
RU2404164C2 (ru) 2005-04-06 2010-11-20 Ф.Хоффманн-Ля Рош Аг Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
US20090264470A1 (en) * 2006-02-21 2009-10-22 Bennett Teresa A CB1 Antagonists and Inverse Agonists
WO2007110449A1 (fr) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Composés de benzènesulfonamide et utilisation de ceux-ci
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (fr) 2006-04-13 2007-10-25 Euro-Celtique S.A. Composés à base de benzènesulfonamide et leur utilisation
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
WO2008038143A2 (fr) * 2006-06-22 2008-04-03 Medichem, S.A. Nouvelles formes solides du rimonabant et procédés de synthèse pour la préparation de celles-ci
US20100076022A1 (en) * 2006-09-01 2010-03-25 Hetero Drugs Limited Novel polymorphs of rimonabant
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
US7928123B2 (en) * 2006-09-25 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
EP1953144A1 (fr) * 2007-01-30 2008-08-06 Sandoz AG Nouvelles formes polymorphes de N-pipéridino-5-(4-chlorophényl)-1-(2, 4-dichlorphényl)-4-méthyl-3-pyrazolecarboxamide
WO2008124118A1 (fr) 2007-04-09 2008-10-16 Purdue Pharma L.P. Composés benzènesulfonylés et leur utilisation
WO2009040659A2 (fr) 2007-09-28 2009-04-02 Purdue Pharma L.P. Composés benzènesulfonamides et leurs utilisations
EP2234966B1 (fr) * 2007-12-18 2013-09-11 Sanofi Derives d'azetidines, leur preparation et leur application en therapeutique
WO2010079241A1 (fr) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones
BRPI0902481B8 (pt) 2009-07-31 2021-05-25 Soc Beneficente De Senhoras Hospital Sirio Libanes composição farmacêutica compreendendo hemopressina e seu uso.
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015609A1 (fr) * 1998-09-11 2000-03-23 Aventis Pharma S.A. Derives d'azetidine, leur preparation et les medicaments les contenant
WO2001064634A1 (fr) * 2000-03-03 2001-09-07 Aventis Pharma S.A. Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
WO2001064633A1 (fr) * 2000-03-03 2001-09-07 Aventis Pharma S.A. Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61928B1 (en) † 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
JPH04360167A (ja) * 1991-06-06 1992-12-14 Mitsubishi Kasei Corp 近接帯電装置
FR2713225B1 (fr) † 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
JPH07209959A (ja) * 1994-01-24 1995-08-11 Ricoh Co Ltd 帯電装置
US5596106A (en) † 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
JP2002516605A (ja) † 1996-10-31 2002-06-04 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のための併用療法
FR2758723B1 (fr) † 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
US6153524A (en) * 1997-07-29 2000-11-28 Silicon Genesis Corporation Cluster tool method using plasma immersion ion implantation
EP0920864A1 (fr) † 1997-12-03 1999-06-09 Pfizer Products Inc. Thérapie de combinaison comprenant un beta-3 agoniste spécifique et un agent anorexigéne
KR100652994B1 (ko) † 1998-09-11 2006-11-30 아방티 파르마 소시에테 아노님 아제티딘 유도체, 이의 제조방법 및 이를 함유하는 약제

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015609A1 (fr) * 1998-09-11 2000-03-23 Aventis Pharma S.A. Derives d'azetidine, leur preparation et les medicaments les contenant
WO2001064634A1 (fr) * 2000-03-03 2001-09-07 Aventis Pharma S.A. Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
WO2001064633A1 (fr) * 2000-03-03 2001-09-07 Aventis Pharma S.A. Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROIETTO, JOSEPH ET AL: "Novel anti-obesity drugs", EXPERT OPIN. INVEST. DRUGS (2000), 9(6), 1317-1326, 2000, XP001004696 *

Also Published As

Publication number Publication date
PL362833A1 (en) 2004-11-02
FR2814678B1 (fr) 2002-12-20
ES2217191T3 (es) 2004-11-01
ZA200303015B (en) 2004-02-26
CA2424934A1 (fr) 2002-04-11
DK1328269T3 (da) 2004-09-20
EP1328269B1 (fr) 2004-05-26
EA200300441A1 (ru) 2003-08-28
DE60103556T3 (de) 2009-04-09
EP1328269A2 (fr) 2003-07-23
AU9393601A (en) 2002-04-15
FR2814678A1 (fr) 2002-04-05
HRP20030249A2 (en) 2005-02-28
JP2004512279A (ja) 2004-04-22
JP4221221B2 (ja) 2009-02-12
YU26103A (sh) 2006-08-17
NO20031521D0 (no) 2003-04-03
SI1328269T1 (en) 2004-10-31
NZ524904A (en) 2004-11-26
EA005924B1 (ru) 2005-08-25
HUP0302044A3 (en) 2005-05-30
SK4032003A3 (en) 2003-09-11
NO20031521L (no) 2003-04-24
DK1328269T5 (da) 2009-03-16
MXPA03002845A (es) 2004-09-10
ATE267595T1 (de) 2004-06-15
ES2217191T5 (es) 2009-02-16
DE60103556T2 (de) 2005-06-30
IL155236A0 (en) 2003-11-23
HUP0302044A2 (hu) 2003-11-28
AU2001293936B2 (en) 2007-01-25
CN1473040A (zh) 2004-02-04
EE200300121A (et) 2005-04-15
SI1328269T2 (sl) 2008-12-31
KR20030036885A (ko) 2003-05-09
DK1328269T4 (da) 2008-11-24
WO2002028346A2 (fr) 2002-04-11
EP1328269B2 (fr) 2008-07-30
PT1328269E (pt) 2004-08-31
BR0114410A (pt) 2004-02-17
TR200401264T4 (tr) 2004-07-21
CN100409845C (zh) 2008-08-13
DE60103556D1 (de) 2004-07-01
BG107739A (bg) 2004-01-30

Similar Documents

Publication Publication Date Title
WO2002028346A3 (fr) Association d'un antagoniste du recepteur cb1 et de sibutramine, pour le traitement de l'obesite
AU2001293936A1 (en) Association of the CB1 receptor antagonist and sibutramin, for treating obesity
HUP0301745A3 (en) Cyclopentanoindoles, compositions containing such compounds and their use
IL158168A0 (en) 5-membered, nitrogen-containing heterocyclic compounds and pharmaceutical compositions containing the same
ZA200003998B (en) Pharmaceutical compositions.
MXPA02012891A (es) Composiciones farmaceuticas de agentes estrogenicos.
IL149030A0 (en) Pharmaceutical compositions containing rifampicin, isoniazid or combinations thereof
HUP0402003A3 (en) Substituted 1,4-benzodiazepines, pharmaceutical compositions containing them and uses thereof
AP2004003024A0 (en) Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same.
MXPA03005257A (es) Composiciones frarmaceuticas de un agonista del receptor de nmda.
WO2002064125A3 (fr) Agent therapeutique contre l'hyperlipidemie
EP1172112B8 (fr) Médicaments préventifs, allégeants ou curatifs de l'hypertension
ZA200210359B (en) Pharmaceutical compositions.
AU2002365655A1 (en) 5-ht7 receptor antagonists
HUP0300928A3 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
AU2002216079A1 (en) Bombesin receptor antagonists
ZA200103074B (en) Packing material for mortar compositions.
AU2002217095A1 (en) Bombesin receptor antagonists
ZA200202030B (en) Isoindoloindolone compounds, a process for their preparation and pharmaceutical compositions containing them.
ZA200202220B (en) Indenoindolone compounds, a process for their preparation and pharmaceutical compositions containing them.
AU2002306956A1 (en) Delta opioid receptor disruptions, compositions and methods related thereto
ZA200204592B (en) Dual-release compositions of a cyclooxygenase-2-inhibitor.
ZA200110500B (en) Pharmaceutical composition.
MXPA03007318A (es) Composicion farmaceutica.
IL153431A0 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-261/03

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001974413

Country of ref document: EP

Ref document number: 524904

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/002845

Country of ref document: MX

Ref document number: 4032003

Country of ref document: SK

Ref document number: PV2003-921

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: P20030249A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 155236

Country of ref document: IL

Ref document number: 2424934

Country of ref document: CA

Ref document number: 1020037004772

Country of ref document: KR

Ref document number: 2002531972

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1-2003-500209

Country of ref document: PH

Ref document number: 2001293936

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003/03015

Country of ref document: ZA

Ref document number: 200303015

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 10773901

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 589/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 018182682

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 200300441

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020037004772

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2003-921

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2001974413

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001974413

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 524904

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 524904

Country of ref document: NZ